MCID: MNN032
MIFTS: 44

Meningococcal Meningitis

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Meningococcal Meningitis

MalaCards integrated aliases for Meningococcal Meningitis:

Name: Meningococcal Meningitis 12 59 15 73
Meningitis, Meningococcal 76 44
Meningitis Meningococcal 55

Characteristics:

Orphanet epidemiological data:

59
meningococcal meningitis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-9/100000 (New Zealand),1-9/1000000 (United States);

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:0080176
ICD9CM 35 036.0
MeSH 44 D008585
Orphanet 59 ORPHA33475
MESH via Orphanet 45 D008585
UMLS via Orphanet 74 C0025294
ICD10 via Orphanet 34 G01* A39.0+
ICD10 33 A39.0
UMLS 73 C0025294

Summaries for Meningococcal Meningitis

Disease Ontology : 12 A bacterial meningitis that has material basis in Neisseria meningitidis infection.

MalaCards based summary : Meningococcal Meningitis, also known as meningitis, meningococcal, is related to meningitis and meningococcemia. An important gene associated with Meningococcal Meningitis is TLR9 (Toll Like Receptor 9), and among its related pathways/superpathways are Innate Immune System and Creation of C4 and C2 activators. The drugs Ciprofloxacin and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include b cells, testes and spinal cord.

Wikipedia : 76 Meningococcal disease describes infections caused by the bacterium Neisseria meningitidis (also termed... more...

Related Diseases for Meningococcal Meningitis

Diseases related to Meningococcal Meningitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Related Disease Score Top Affiliating Genes
1 meningitis 31.7 CFP MBL2 TLR9
2 meningococcemia 30.8 CFP MBL2
3 membranoproliferative glomerulonephritis 30.0 CFH CFP
4 glomerulonephritis 29.9 CFH CFP TLR9
5 complement deficiency 29.5 C7 CFP MBL2
6 adult dermatomyositis 10.4 MBL2 TLR9
7 scabies 10.4 CFP MBL2
8 mannose-binding lectin deficiency 10.3 CFP MBL2
9 neisseria meningitidis infection 10.3 CFP MBL2
10 cryptococcosis 10.3 MBL2 TLR9
11 3mc syndrome 10.3 CFP MBL2
12 streptococcal meningitis 10.3 CFP MBL2
13 bacterial meningitis 10.2 CFP TLR9
14 immunodeficiency due to a late component of complement deficiency 10.2 C6 C7
15 aspergillosis 10.2 MBL2 TLR9
16 cerebritis 10.1
17 pericarditis 10.1
18 endophthalmitis 10.1
19 arthritis 10.0
20 waterhouse-friderichsen syndrome 10.0
21 iga glomerulonephritis 10.0 CFP MBL2
22 cardiac tamponade 10.0
23 pulmonary tuberculosis 10.0 MBL2 TLR9
24 aging 9.9
25 malaria 9.9
26 rigidity and multifocal seizure syndrome, lethal neonatal 9.9
27 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.9
28 subdural empyema 9.9
29 hemopericardium 9.9
30 pericardial effusion 9.9
31 panophthalmitis 9.9
32 paraplegia 9.9
33 influenza 9.9
34 vasculitis 9.9
35 haemophilus influenzae 9.9
36 spinal cord infarction 9.9
37 opportunistic mycosis 9.8 ST5 TLR9
38 cardiac arrhythmia 9.7
39 systemic lupus erythematosus 9.7
40 chiari malformation type ii 9.7
41 atrioventricular dissociation 9.7
42 stroke, ischemic 9.7
43 aceruloplasminemia 9.7
44 complement component 5 deficiency 9.7
45 ataxia-oculomotor apraxia 3 9.7
46 cataract 9.7
47 hydrocephalus 9.7
48 thrombosis 9.7
49 partial lipodystrophy 9.7
50 sensorineural hearing loss 9.7

Graphical network of the top 20 diseases related to Meningococcal Meningitis:



Diseases related to Meningococcal Meningitis

Symptoms & Phenotypes for Meningococcal Meningitis

Drugs & Therapeutics for Meningococcal Meningitis

Drugs for Meningococcal Meningitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
2 Antibodies Phase 4,Phase 2,Phase 3
3 Immunoglobulins Phase 4,Phase 2,Phase 3
4 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
5 Anti-Bacterial Agents Phase 4
6 Anti-Infective Agents Phase 4
7 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
8 Cytochrome P-450 Enzyme Inhibitors Phase 4
9 Topoisomerase Inhibitors Phase 4
10 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2
11
Hydroxocobalamin Approved Phase 2, Phase 3,Phase 3 13422-51-0 11953898 44475014
12
Aluminum hydroxide Approved, Investigational Phase 2, Phase 3 21645-51-2
13
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3,Phase 3 68-19-9 44176380
14
Lactitol Investigational Phase 3,Phase 2 585-86-4 3871
15 Vitamin B 12 Phase 2, Phase 3,Phase 3
16 Cathartics Phase 3,Phase 2
17 Gastrointestinal Agents Phase 3,Phase 2
18 Laxatives Phase 3,Phase 2
19 Adjuvants, Immunologic Phase 2, Phase 3
20 Antacids Phase 2, Phase 3
21 Anti-Ulcer Agents Phase 2, Phase 3
22
Cobalamin Nutraceutical Phase 2, Phase 3,Phase 3 13408-78-1 6438156
23 Vitamin B12 Nutraceutical Phase 2, Phase 3,Phase 3
24 Antipyretics Phase 2

Interventional clinical trials:

(show top 50) (show all 76)
# Name Status NCT ID Phase Drugs
1 Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine Unknown status NCT00262015 Phase 4
2 Ciprofloxacin for the Prevention of Meningococcal Meningitis Completed NCT02724046 Phase 4 Ciprofloxacin
3 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
4 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier Completed NCT02633787 Phase 4
5 Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
6 Persistence of Antibody Response to N. Meningitidis Group C in Children Completed NCT00316654 Phase 4
7 Kinetics of B Cell Response in Infants Menjugate Vaccination Completed NCT00310700 Phase 4
8 Persistence of Immune Response After Vaccination With MCC Completed NCT00310687 Phase 4
9 Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine Completed NCT00310713 Phase 4
10 Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea Active, not recruiting NCT02864927 Phase 4
11 Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018 Not yet recruiting NCT03431675 Phase 4 Ciprofloxacin
12 Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years Completed NCT01423084 Phase 3
13 Comparison of Two Meningococcal ACWY Conjugate Vaccines Completed NCT01192997 Phase 2, Phase 3
14 Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine Completed NCT01148017 Phase 3
15 Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine Completed NCT00856297 Phase 3
16 Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers Completed NCT00667602 Phase 3
17 Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12 Completed NCT00944034 Phase 2, Phase 3
18 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers Completed NCT02955797 Phase 3
19 Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants Completed NCT00657709 Phase 3
20 Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28 Completed NCT01894919 Phase 3
21 Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 Completed NCT01717638 Phase 3
22 A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults Completed NCT01478347 Phase 3
23 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults Completed NCT00474487 Phase 3
24 A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Chil Completed NCT01339923 Phase 3
25 A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea Completed NCT01274897 Phase 3
26 Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life Completed NCT01214837 Phase 3
27 Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 Completed NCT01148524 Phase 2, Phase 3
28 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults Completed NCT00450437 Phase 3
29 Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years Completed NCT00329901 Phase 3
30 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older Completed NCT02842866 Phase 3
31 Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Completed NCT02842853 Phase 3
32 Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Completed NCT02752906 Phase 3
33 Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects Completed NCT01519713 Phase 3
34 Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers Completed NCT00483574 Phase 3
35 Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers Completed NCT00422292 Phase 3
36 A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Completed NCT00384397 Phase 3
37 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents Completed NCT00518180 Phase 3
38 Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine Completed NCT01453348 Phase 3
39 Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants Completed NCT00161928 Phase 3
40 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Completed NCT01466387 Phase 3
41 Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age Completed NCT00310674 Phase 3
42 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants Completed NCT00474526 Phase 3
43 Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children Completed NCT00311415 Phase 3
44 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults Completed NCT01755689 Phase 3
45 Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US Recruiting NCT03537508 Phase 3
46 Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children Recruiting NCT03476135 Phase 3
47 Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years Active, not recruiting NCT03077438 Phase 3
48 Conjugate Vaccine Against Meningococcus C a Brazilian Project Not yet recruiting NCT02858570 Phase 2, Phase 3
49 Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe Not yet recruiting NCT03547271 Phase 3
50 Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine Completed NCT01897402 Phase 2

Search NIH Clinical Center for Meningococcal Meningitis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: meningitis, meningococcal

Genetic Tests for Meningococcal Meningitis

Anatomical Context for Meningococcal Meningitis

MalaCards organs/tissues related to Meningococcal Meningitis:

41
B Cells, Testes, Spinal Cord, Neutrophil, Medulla Oblongata, Skin, Brain

Publications for Meningococcal Meningitis

Articles related to Meningococcal Meningitis:

(show top 50) (show all 509)
# Title Authors Year
1
A refugee patient with meningococcal meningitis type B. ( 29757696 )
2018
2
Meningococcal meningitis with neurological complications and meningococcemia due to serogroup W sequence type 11 complex. ( 29373268 )
2018
3
Long-term health and socioeconomic consequences of childhood and adolescent onset of meningococcal meningitis. ( 29923041 )
2018
4
Reply to "A refugee patient with meningococcal meningitis type B." ( 29792550 )
2018
5
Cerebral Venous Sinus Thrombosis in a Patient with Meningococcal Meningitis. ( 29468001 )
2018
6
Meningococcal Meningitis Complicated by Ventriculitis in an Infant. ( 29417667 )
2018
7
Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial. ( 29944651 )
2018
8
Reversible splenial lesion of the corpus callosum associated with meningococcal meningitis. ( 28131233 )
2017
9
Uncommon mixed outbreak of pneumococcal and meningococcal meningitis in Jirapa District, Upper West Region, Ghana, 2016. ( 29622828 )
2017
10
Deep coal mining and meningococcal meningitis in England and Wales, 1931-38: Ecological study, with implications for deep shaft mining activities worldwide. ( 28813690 )
2017
11
Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa. ( 28081671 )
2017
12
An atypical form of infantile meningococcal meningitis. ( 28389430 )
2017
13
Bilateral abducens nerve palsy as the initial clinical manifestation of meningococcal meningitis. ( 27876190 )
2017
14
Ciprofloxacin for contacts of cases of meningococcal meningitis as an epidemic response: study protocol for a cluster-randomized trial. ( 28646924 )
2017
15
Detection of meningococcal meningitis in cerebrospinal fluid of patients with neurological disorders in government hospitals of Karachi. ( 27812059 )
2016
16
A case of meningococcal meningitis that was difficult to treat owing to concurrent ventriculitis. ( 27151225 )
2016
17
Meningococcal meningitis: clinical and laboratorial characteristics, fatality rate and variables associated with in-hospital mortality. ( 27901251 )
2016
18
Pattern of the meningococcal meningitis outbreak in Northern Nigeria, 2009. ( 26724773 )
2016
19
Notes from the Field: Expanded Chemoprophylaxis Offered in Response to a Case of Meningococcal Meningitis in an Elementary School - Indiana, 2015. ( 27227736 )
2016
20
Serogroup-Specific Characteristics of Localized Meningococcal Meningitis Epidemics in Niger 2002-2012 and 2015: Analysis of Health Center Level Surveillance Data. ( 27657530 )
2016
21
Neonatal Meningococcal Meningitis In France From 2001 To 2013. ( 27753774 )
2016
22
Neonatal Meningococcal Meningitis in France from 2001 to 2013. ( 27404598 )
2016
23
The Dual Role of Lipids of the Lipoproteins in Trumenba, a Self-Adjuvanting Vaccine Against Meningococcal Meningitis B Disease. ( 27604766 )
2016
24
Callosal disconnection syndrome after ischemic stroke of the corpus callosum due to meningococcal meningitis: A case report. ( 27653875 )
2016
25
Atypical clinical presentation of meningococcal meningitis: a case report. ( 27668905 )
2016
26
Invasive Meningococcal Meningitis Serogroup C Outbreak in Northwest Nigeria, 2015 - Third Consecutive Outbreak of a New Strain. ( 27508101 )
2016
27
Meningococcal meningitis: vaccination outbreak response and epidemiological changes in the African meningitis belt. ( 25878213 )
2015
28
Incidence, carriage and case-carrier ratios for meningococcal meningitis in the African meningitis belt: a systematic review and meta-analysis. ( 25658307 )
2015
29
Meningococcal meningitis with meningococcemia: a rare sporadic case in an elderly patient with no history of contact with infected individuals. ( 25420647 )
2015
30
Meningococcal Meningitis Surveillance in the African Meningitis Belt, 2004-2013. ( 26553668 )
2015
31
Preparedness for outbreaks of meningococcal meningitis due to Neisseria meningitidis serogroup C in Africa: recommendations from a WHO expert consultation. ( 26591025 )
2015
32
Prevalence of meningococcal meningitis in China from 2005 to 2010. ( 25444796 )
2015
33
A case of meningococcal meningitis with multiple cerebellar microbleeds detected by susceptibility-weighted imaging. ( 26489936 )
2015
34
Climate Regimes, El NiA+o-Southern Oscillation, and Meningococcal Meningitis Epidemics. ( 26284234 )
2015
35
A Syrian patient diagnosed with meningococcal meningitis serogroup B. ( 24785992 )
2014
36
Spatio-temporal factors associated with meningococcal meningitis annual incidence at the health centre level in Niger, 2004-2010. ( 24852960 )
2014
37
Inhibition of matrix metalloproteinases attenuates brain damage in experimental meningococcal meningitis. ( 25551808 )
2014
38
Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. ( 24035220 )
2014
39
Corticosteroid-induced meningococcal meningitis in a patient with chronic meningococcemia. ( 24577072 )
2014
40
Epidemiological characteristics of meningococcal meningitis in the area of Zenica-Doboj Canton in period from 2008 to 2012. ( 25195353 )
2014
41
Multiple cerebral sinus thromboses complicating meningococcal meningitis: a pediatric case report. ( 24923843 )
2014
42
A Syrian patient diagnosed with meningococcal meningitis serogroup B. ( 25424959 )
2014
43
An Adolescent Boy Presenting with Complicated Meningococcal Meningitis Serogroup A: What Is the State of Community Awareness for This Serious Disease? ( 26175987 )
2014
44
A five-year field assessment of rapid diagnostic tests for meningococcal meningitis in Niger by using the combination of conventional and real-time PCR assays as a gold standard. ( 24300442 )
2014
45
Epidemiological characteristics of meningococcal meningitis in the area of zenica-doboj canton in period from 2008 to 2012. ( 25568534 )
2014
46
Meningococcal meningitis C in Tamil Nadu, public health perspectives. ( 25657960 )
2014
47
Cerebrospinal fluid complement activation in patients with pneumococcal and meningococcal meningitis. ( 24412248 )
2014
48
A country-wide field evaluation of rapid diagnostic test for meningococcal meningitis. ( 24627423 )
2014
49
Images in clinical medicine. Hypoglossal nerve palsy during meningococcal meningitis. ( 25295510 )
2014
50
Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination. ( 24313998 )
2013

Variations for Meningococcal Meningitis

Expression for Meningococcal Meningitis

Search GEO for disease gene expression data for Meningococcal Meningitis.

Pathways for Meningococcal Meningitis

GO Terms for Meningococcal Meningitis

Cellular components related to Meningococcal Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.43 C6 C7 CFH CFP MBL2 TLR9
2 membrane attack complex GO:0005579 8.62 C6 C7

Biological processes related to Meningococcal Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.61 C6 C7 CFP
2 defense response to bacterium GO:0042742 9.58 CFP MBL2 TLR9
3 regulation of complement activation GO:0030449 9.56 C6 C7 CFH CFP
4 complement activation, classical pathway GO:0006958 9.5 C6 C7 MBL2
5 innate immune response GO:0045087 9.43 C6 C7 CFH CFP MBL2 TLR9
6 cytolysis GO:0019835 9.37 C6 C7
7 complement activation, alternative pathway GO:0006957 9.33 C7 CFH CFP
8 complement activation GO:0006956 9.02 C6 C7 CFH CFP MBL2

Sources for Meningococcal Meningitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....